Research Topics
Genomes and GenesSpecies | David J StewartSummaryAffiliation: The University of Texas Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancerDavid J Stewart
Department of Thoracic Head and Neck Medical Oncology, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Crit Rev Oncol Hematol 75:173-234. 2010..To date, resistance-modulating strategies have generally not proven clinically useful in lung cancer, although small randomized trials suggest a modest benefit of verapamil and related agents in NSCLC...
Phase II study of alternating chemotherapy regimens for advanced non-small cell lung cancerDavid J Stewart
The Ottawa Regional Cancer Centre, Cancer Care Ontario, Ottawa, Ontario, Canada
Lung Cancer 44:241-9. 2004..We assessed the use of alternating drugs with differing mechanisms of action as treatment for advanced non-small cell lung cancer...
Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomasDavid J Stewart
M D Anderson Cancer Center, Houston, Texas, USA
Clin Cancer Res 15:3881-8. 2009..By hypomethylating genes, decitabine may up-regulate factors required for chemotherapeutic cytotoxicity. Platinum-resistant cells may have reduced expression of the copper/platinum transporter CTR1...- Equipoise lost: ethics, costs, and the regulation of cancer clinical researchDavid J Stewart
Department of Thoracic Head and Neck Medical Oncology, M D Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 28:2925-35. 2010..We outline suggested solutions... - Exponential decay nonlinear regression analysis of patient survival curves: preliminary assessment in non-small cell lung cancerDavid J Stewart
Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States
Lung Cancer 71:217-23. 2011..We conducted a preliminary feasibility assessment of EDNRA of patient survival curves... - Extensive disease small cell lung cancer dose-response relationships: implications for resistance mechanismsDavid J Stewart
Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
J Thorac Oncol 5:1826-34. 2010..Some studies (but not others) suggested that high doses are beneficial in small cell lung cancer (SCLC). We hypothesized that dose-response curve (DRC) shape reflects resistance mechanisms... - Mechanisms of resistance to cisplatin and carboplatinDavid J Stewart
Section of Experimental Therapeutics, Department of Thoracic Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Crit Rev Oncol Hematol 63:12-31. 2007.... - Foreword--new directions for topotecan in lung cancer treatmentDavid J Stewart
The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Room FC-9-3062, Houston, Texas 77030, USA
Oncologist 9:1-3. 2004 - Chemotherapy dose--response relationships in non-small cell lung cancer and implied resistance mechanismsDavid J Stewart
The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 432, Houston, TX 77030, USA
Cancer Treat Rev 33:101-37. 2007.... - Topotecan in the first-line treatment of small cell lung cancerDavid J Stewart
The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Room FC 9 3062, Houston, Texas 77030, USA
Oncologist 9:33-42. 2004..Additional clinical trials to investigate topotecan-based combination regimens and confirm their role in the first-line treatment of SCLC are under way... - Update on the role of topotecan in the treatment of non-small cell lung cancerDavid J Stewart
The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 0432, Houston, Texas 77030, USA
Oncologist 9:43-52. 2004..Herein, the future role of topotecan in the first- and second-line treatment of NSCLC and the potential role of resistance mechanisms obtained from in vivo dose-response studies in designing future combination regimens are discussed... - Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapyApar Pataer
Departments of Thoracic and Cardiovascular Surgery, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
J Thorac Oncol 7:825-32. 2012.... - Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapyXifeng Wu
Department of Epidemiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1340, Houston, TX 77030, USA
J Natl Cancer Inst 103:817-25. 2011..Interindividual variation in genetic background may influence the response to chemotherapy and overall survival for patients with advanced-stage non-small cell lung cancer (NSCLC)... - Tissue platinum concentration and tumor response in non-small-cell lung cancerEric S Kim
The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 463, Houston, TX 77030, USA
J Clin Oncol 30:3345-52. 2012..We assessed the effects of tissue platinum concentrations on response and survival in NSCLC... - Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinomaWilliam N William
Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 116:2409-15. 2010..A phase 2 trial was conducted to estimate the efficacy of this regimen in previously untreated patients with extensive SCLC... - Genetic variations in the transforming growth factor-beta pathway as predictors of survival in advanced non-small cell lung cancerMoubin Lin
Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Carcinogenesis 32:1050-6. 2011..These results suggest that genetic variations in the TGF-β pathway are potential predictors of overall survival in NSCLC patients treated with platinum-based chemotherapy with or without radiation... - Plasma biomarkers correlating with clinical outcome in a phase II study of sorafenib in advanced NSCLCGeorge R Blumenschein
University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
Cancer Biomark 10:287-98. 2011.... - Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancerMichelle A T Hildebrandt
Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
PLoS ONE 5:e12402. 2010..These results suggest that genetic variations among inflammation pathway genes may modulate the development of radiation-induced toxicity and, ultimately, help in identifying patients who are at an increased likelihood for such events... - Genetic variants in cell cycle control pathway confer susceptibility to lung cancerWei Wang
Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 13:5974-81. 2007..To test the hypothesis that common sequence variants of cell cycle control genes may affect lung cancer predisposition... - Systematic evaluation of apoptotic pathway gene polymorphisms and lung cancer riskJie Lin
Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Carcinogenesis 33:1699-706. 2012..Future studies are needed to identify the causal SNPs and elucidate the underlying molecular mechanisms... - Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humansCharles Lu
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
PLoS ONE 7:e34833. 2012..No drug strategies currently exist targeting loss-of-function genetic abnormalities. We report the first in-human systemic gene therapy clinical trial of tumor suppressor gene TUSC2... - Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinomaAnne S Tsao
Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
J Thorac Oncol 6:2104-11. 2011..Baseline tumor specimens, serum, and perfusion computed tomography (CT) scans were obtained for supportive evaluation... - Phase II study of dasatinib in patients with advanced non-small-cell lung cancerFaye M Johnson
Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
J Clin Oncol 28:4609-15. 2010..We tested the hypotheses that the activation of epidermal growth factor receptor (EGFR) or SFK or modulation of serum cytokines may predict a response to dasatinib... - The BATTLE trial: personalizing therapy for lung cancerEdward S Kim
Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Cancer Discov 1:44-53. 2011.... - High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutationMaria Ines Nunez
Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
J Thorac Oncol 7:833-40. 2012..Information on the protein expression of these receptors in non-small-cell lung carcinoma (NSCLC) is limited... - PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapyXia Pu
Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Lung Cancer 71:82-8. 2011..With further validation, our findings may provide additional biomarkers for customized treatment of platinum-based chemotherapy for NSCLC... - Number of metastatic sites is a strong predictor of survival in patients with nonsmall cell lung cancer with or without brain metastasesYun Oh
Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 1402, USA
Cancer 115:2930-8. 2009..The staging system for non-small cell lung cancer (NSCLC) does not consider tumor burden or number of metastatic sites, although oligometastases are more favorable... - Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinibBanibrata Sen
Department of Thoracic Head and Neck Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Sci Transl Med 4:136ra70. 2012..Moreover, the potential synthetic lethality of combination therapy including dasatinib and BRAF inhibitors may lead to additional therapeutic options against cancers with wild-type BRAF... - Deficient G2-M and S checkpoints are associated with increased lung cancer risk: a case-control analysisJinliang Xing
Department of Epidemiology, Unit 1340, The University of Texas M D Anderson Cancer Center, 1155 Pressler Boulevard, Houston, TX 77030, USA
Cancer Epidemiol Biomarkers Prev 16:1517-22. 2007..Additionally, cell accumulation indices at both G2-M and S phases were not associated with clinical stages. We conclude that attenuated functions of G2-M and S cell cycle checkpoints might be susceptibility markers for lung cancer... - Targeted therapy in non-small-cell lung cancer--is it becoming a reality?Filip Janku
Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Nat Rev Clin Oncol 7:401-14. 2010..Novel drugs aimed at these abnormalities are already in the clinic. This Review outlines the current state-of-the-art research for targeted therapy in NSCLC... - Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for the treatment of non-small cell lung cancerWilliam N William
Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
J Thorac Oncol 2:745-50. 2007..Preclinical data suggest that this drug might also enhance the antineoplastic effects of chemotherapy... - DNA repair capacity in peripheral lymphocytes predicts survival of patients with non-small-cell lung cancer treated with first-line platinum-based chemotherapyLi E Wang
The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
J Clin Oncol 29:4121-8. 2011..In this larger independent study of 591 patients with NSCLC, we further evaluated whether DRC in peripheral lymphocytes predicts survival of patients with NSCLC who receive platinum-based chemotherapy... - Many patients 80 years and older with advanced non-small cell lung cancer (NSCLC) can tolerate chemotherapyOzden Altundag
Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
J Thorac Oncol 2:141-6. 2007..43). Hematologic and nonhematologic toxicities were similar. Our data indicate that selected patients 80 years of age and older may tolerate and benefit from chemotherapy, and prospective evaluation of these patients is indicated... - Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancerGeorge R Blumenschein
The M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 432, Houston, TX 77030 4009, USA
J Clin Oncol 27:4274-80. 2009..We evaluated the antitumor response and tolerability of sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer (NSCLC), most of whom had received prior platinum-based chemotherapy... - Novel therapeutic targets in non-small cell lung cancerFilip Janku
Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
J Thorac Oncol 6:1601-12. 2011..This review describes molecular targets in non-small cell lung cancer that are in development or being clinically applied and their implications for developing novel anticancer therapies for this previously refractory malignancy... - Potential of CXCR4 antagonists for the treatment of metastatic lung cancerJan A Burger
Department of Leukemia, Unit 428, The University of Texas MD Anderson Cancer Center, PO Box 301402, Houston, TX 77230 1402, USA
Expert Rev Anticancer Ther 11:621-30. 2011..In addition, we review the current status of the preclinical and clinical development of CXCR4 antagonists... - Sorafenib-induced premalignant and malignant skin lesionsVictoria L Williams
Baylor College of Medicine, Houston, TX, USA
Int J Dermatol 50:396-402. 2011..To review characteristics of patients who develop premalignant and malignant skin lesions while on sorafenib therapy and discuss implications for subsequent treatment of their primary malignancies... - Systemic therapy for lung cancer brain metastases: a rationale for clinical trialsYun Oh
Department of Thoracic, Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Oncology (Williston Park) 22:168-78; discussion 178, 183, 188 passim. 2008..This collective information describes an area in need of therapeutic development and supports an initiative to evaluate novel targeted therapies for lung cancer brain metastases... - Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic featuresLuisa M Solis
Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 16:3743-53. 2010.... - Outcomes of Phase II Clinical Trials with Single-Agent Therapies in Advanced/Metastatic Non-Small Cell Lung Cancer Published between 2000 and 2009Filip Janku
Authors Affiliations Departments of Investigational Cancer Therapeutics Phase I Clinical Trials Program, Biostatistics, and Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Clin Cancer Res 18:6356-63. 2012.... - ATM sequence variants associate with susceptibility to non-small cell lung cancerHushan Yang
Department of Epidemiology, The University of Texas M D Anderson Cancer Center, Houston, TX
Int J Cancer 121:2254-9. 2007.... - Imaging of the patient with non-small cell lung cancerReginald F Munden
Division of Diagnostic Imaging, Department of Diagnostic Radiology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
Radiology 237:803-18. 2005..This article reviews the role of imaging in patients with non-small cell lung cancer, with an emphasis on the radiologic imaging findings relevant for each specialty... - Ultimate fate of oncology drugs approved by the us food and drug administration without a randomized TrialApostolia Maria Tsimberidou
The University of Texas M D Anderson Cancer Center, Department of Investigational Cancer Therapeutics, Unit 455, 1515 Holcombe Blvd, Houston, TX 77030, USA
J Clin Oncol 27:6243-50. 2009..However, several oncology drugs have been approved on the basis of objective end points without a randomized trial. We reviewed the long-term safety and efficacy of such agents... - CXCR4 chemokine receptor antagonists: perspectives in SCLCJan A Burger
University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX 77230 1402, USA
Expert Opin Investig Drugs 18:481-90. 2009..Here, we summarize preclinical data about CXCR4 in SCLC, and the current status of the preclinical and clinical development of CXCR4 antagonists... - Tumor cavitation during therapy with antiangiogenesis agents in patients with lung cancerEdith M Marom
Department of Diagnostic Imaging, University of Texas, M D Anderson Cancer Center, Sheba Medical Center, Tel Hashomer, Israel
J Thorac Oncol 3:351-7. 2008.... - Gefitinib maintenance in stage III non-small-cell lung cancerDavid J Stewart
J Clin Oncol 26:4849-50; author reply 4850-1. 2008 - Re: Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non-small cell lung cancerDavid J Stewart
J Natl Cancer Inst 100:445-6; author reply 446. 2008 - Combining epigenetic and cytotoxic therapy in the treatment of solid tumorsElizabeth R Plimack
J Clin Oncol 25:4519-21. 2007
Research Grants
- Changes in Tumor DNA Methylation with DecitabineDavid Stewart; Fiscal Year: 2006..This preliminary look at individual genes may provide a molecular rationale for future decitabine therapeutic studies in specific relevant tumor types. ..